Risk Literacy
The last module in the foundations track, and the only one whose conclusion is sometimes "nobody knows". Learning to say that accurately, and to tell it apart from "it is safe" and from "it is dangerous", is the actual skill.
Three kinds of risk
People collapse these into one word and then argue past each other for a thousand comments.
| Category | Definition | What you can do about it |
|---|---|---|
| Known risk | Documented adverse effects with rates attached, from trials or post-marketing surveillance. | Read the label, weigh it, monitor for it. |
| Unknown risk | Nobody has looked, or the studies are too small to detect anything but the obvious. | Nothing directly. You can only size the ignorance. |
| Unknowable risk | Effects over timescales longer than any study has run. | Nothing at all. This category never empties. |
The critical move: the absence of reported adverse effects is not evidence of safety when nobody has been reporting. A compound with no documented side effects and no trials has an empty file, not a clean one. Approved drugs appear to have long side-effect lists because somebody counted. Grey-market compounds appear to have short ones for the opposite reason.
A long list of side effects is a sign that someone looked. A short one is usually a sign that nobody did.
The evidence hierarchy
When someone says "there are studies", ask which rung.
| Level | What it establishes | What it does not |
|---|---|---|
| In vitro (cells) | A mechanism is chemically possible. | Anything about a whole organism. |
| Rodent | An effect occurs in a rodent, at some dose. | That it occurs in humans, or at what dose. |
| Larger animal / primate | Better physiological proximity. | Still not human data. |
| Human Phase I | Tolerability and pharmacokinetics in a small healthy group. | Whether it works. |
| Human Phase II | Preliminary efficacy, dose ranging. | Rare adverse events; long-term outcomes. |
| Human Phase III | Efficacy against comparator at scale. | Effects rarer than roughly 1 in 1,000. |
| Post-marketing | Rare events, long-term signals, real-world populations. | Nothing above it. |
Most compounds in the grey market sit on the first two rungs. That is not a scandal. It is the ordinary state of an early molecule. It becomes a problem only when a claim from rung two is presented with the confidence appropriate to rung six.
The attrition is worth internalising: a large majority of drug candidates that succeed in animals fail in humans, and a substantial share of those failures are safety failures rather than efficacy failures. "It worked in rats" is the beginning of a story with a high mortality rate.
Why you cannot use the rodent dose
A study reports 10 mg/kg in rats. A 70 kg human multiplies through to 700 mg. That number is wrong, and not by a small margin.
Metabolic rate does not scale linearly with body mass; it scales with roughly the three-quarter power, which means smaller animals burn through compounds far faster per kilogram than large ones. Regulatory practice converts between species using body surface area rather than mass. For rat to human the conversion divides by a factor of about six, and for mouse to human by about twelve.1 These conversions are a starting point for designing a first human trial under medical supervision. They are not a method for calculating a personal dose, and using them as one skips the entire purpose of a Phase I study.
Risks specific to this field
Contamination
The risk that does not depend on the compound being wrong in any way. Non-GMP material can carry bacterial contamination, bacterial endotoxin (which survives sterilisation and causes fever and systemic inflammatory response), residual synthesis solvents, heavy metals from catalysts, and truncated or deleted sequences left over from imperfect synthesis. An injected contaminant bypasses every barrier the body has. This is the strongest single argument for the document literacy taught in PEP 301.
Immunogenicity
The immune system can decide that an injected peptide is foreign and raise antibodies against it. Two consequences: the compound stops working as the antibodies clear it, and, in the serious case, if the peptide closely resembles something your body makes, the antibodies may cross-react with the native molecule. Aggregated material is substantially more immunogenic than properly handled material, which is the direct link between Module 06 and this one. Shaking a vial is not only a potency question.
Growth signalling
Compounds that promote proliferation and angiogenesis promote it in whatever is present. The theoretical concern that growth-promoting signals could accelerate an undetected malignancy is exactly that: theoretical, unquantified, and unresolved for most of the compounds in question. It is also not dismissible, and it is the reason growth-factor pathways receive particular caution in clinical settings.
Masking
An under-discussed mechanism of harm. A compound that reduces pain from an injury has not repaired the injury. Removing the signal that was limiting your activity permits more loading of a structure that could not previously tolerate it. The subjective experience is improvement; the trajectory can be the opposite.
Interaction and stacking
Two compounds, each with an incomplete safety profile, do not produce a combined profile that is the sum of the parts. They produce one that has never been characterised at all. Every addition to a stack multiplies the unknowns and destroys your ability to attribute any effect, good or bad, to any particular thing. PEP 401 treats this properly.
Why anecdote fails here specifically
Forum reports are not worthless, but they are subject to a stack of distortions that all point the same direction.
- No denominator. You see the people who posted. You cannot see how many took it and said nothing, and you certainly cannot see the ones who stopped participating.
- Survivorship. People who had a bad experience frequently leave the community rather than write it up.
- Unknown exposure. Without a certificate of analysis, the report is of an unknown quantity of an unverified substance. It is not a report about the compound; it is a report about a vial.
- Confounding. The person also changed their training, their sleep, their diet, and their expectations, usually in the same week.
- Expectation effects. Substantial, well documented, and largest for exactly the subjective endpoints most often reported: energy, mood, recovery, wellbeing.
- Recency. Enthusiasm is written at week three. The follow-up at month nine is usually never written.
The useful thing anecdote can supply is a signal to investigate: many independent reports of the same unusual specific effect are worth a closer look. What it cannot supply is a rate, a mechanism, or a safety conclusion.
Red flags
- "No side effects"
- Nothing that does anything has no side effects. This claim describes the seller's evidence base, not the compound.
- A protocol supplied by the person selling it
- The dose recommendation and the sales incentive are pointing the same way.
- No certificate of analysis, or one with no batch number
- An unbatched certificate cannot be connected to the vial in your hand.
- Comparisons to an approved drug it is not
- "Works like [approved drug]" is a claim requiring the trial data that the approved drug has and this one does not.
- Urgency
- Restocking anxiety, expiring discounts, and closing group buys are sales mechanics, not information.
- An unfalsifiable explanation for it not working
- If every negative result is attributable to your dose, your timing, or your sourcing, the claim cannot be tested.
Stopping rules
Decide in advance what would make you stop, and write it down before you start. A rule invented while experiencing the symptom is not a rule; it is a negotiation, and you will lose it.
Some things end the conversation immediately and are matters for urgent medical care rather than deliberation: signs of a systemic allergic reaction such as swelling of face, lips, or throat, difficulty breathing, or widespread hives; chest pain; fever with rigors after an injection, which may indicate contamination; a spreading, hot, painful injection site; sudden severe abdominal pain; vision changes; or any neurological symptom of sudden onset.
If you are seeking medical care, say exactly what you took, how much, and when. Clinicians are not there to prosecute you and cannot treat what they do not know about. Omitting it is the one decision in this module with no upside at all.
The honest summary
For most compounds discussed in this field, the accurate statement is: the mechanism is plausible, the preclinical data are real but preliminary, human data are thin or absent, the material in circulation is of unverified quality, the long-term profile is unknown, and nobody, including anyone selling it and including this school, can tell you the actual risk with a number attached.
That statement is uncomfortable and it is not a reason to stop reading. It is the reason to keep reading. Everything in PEP 301 and PEP 401 exists to reduce the parts of that sentence that are within your control, and to be clear-eyed about the parts that are not.
You have finished the foundations track. You can define what a peptide is, describe how it signals, place it in a legal category, convert its units, reconstitute it correctly, store it properly, and reason about its risks without deferring to whoever sounds most confident. That is the whole point of a foundation: everything above it now has something to stand on.
What you should be able to do now
- Separate known, unknown, and unknowable risk in any specific claim.
- Place a cited study on the evidence hierarchy and state what it cannot establish.
- Explain why a rodent mg/kg figure does not convert to a human dose.
- Name the field-specific risk categories and the handling error linked to each.
- List the distortions that make forum consensus unreliable.
- State your own stopping rules before starting anything.
- Body-surface-area conversion factors between species are standard in regulatory guidance for estimating a maximum recommended starting dose in initial human trials. They are cited here to illustrate the magnitude of the correction, not as a dosing method.